These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 30212763)

  • 1. Design, synthesis, and biological evaluations of phenylpropiolic acid derivatives as novel GPR40 agonists.
    Jiang XW; Jiang BE; Liu H; Liu ZT; Hu LL; Liu M; Lu W; Zhang HK
    Eur J Med Chem; 2018 Oct; 158():123-133. PubMed ID: 30212763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and biological evaluation of 3-aryl-3-(4-phenoxy)-propionic acid as a novel series of G protein-coupled receptor 40 agonists.
    Song F; Lu S; Gunnet J; Xu JZ; Wines P; Proost J; Liang Y; Baumann C; Lenhard J; Murray WV; Demarest KT; Kuo GH
    J Med Chem; 2007 Jun; 50(12):2807-17. PubMed ID: 17500511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of Potent and Orally Bioavailable GPR40 Full Agonists Bearing Thiophen-2-ylpropanoic Acid Scaffold.
    Li H; Huang Q; Chen C; Xu B; Wang HY; Long YQ
    J Med Chem; 2017 Apr; 60(7):2697-2717. PubMed ID: 28277660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules.
    Briscoe CP; Peat AJ; McKeown SC; Corbett DF; Goetz AS; Littleton TR; McCoy DC; Kenakin TP; Andrews JL; Ammala C; Fornwald JA; Ignar DM; Jenkinson S
    Br J Pharmacol; 2006 Jul; 148(5):619-28. PubMed ID: 16702987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Yhhu4488, a novel GPR40 agonist, promotes GLP-1 secretion and exerts anti-diabetic effect in rodent models.
    Guo DY; Li DW; Ning MM; Dang XY; Zhang LN; Zeng LM; Hu YH; Leng Y
    Biochem Biophys Res Commun; 2015 Oct; 466(4):740-7. PubMed ID: 26417688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent Updates on Free Fatty Acid Receptor 1 (GPR-40) Agonists for the Treatment of Type 2 Diabetes Mellitus.
    Rani L; Grewal AS; Sharma N; Singh S
    Mini Rev Med Chem; 2021; 21(4):426-470. PubMed ID: 33100202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and biological activity of potent and orally available G protein-coupled receptor 40 agonists.
    Sasaki S; Kitamura S; Negoro N; Suzuki M; Tsujihata Y; Suzuki N; Santou T; Kanzaki N; Harada M; Tanaka Y; Kobayashi M; Tada N; Funami M; Tanaka T; Yamamoto Y; Fukatsu K; Yasuma T; Momose Y
    J Med Chem; 2011 Mar; 54(5):1365-78. PubMed ID: 21319751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists.
    Nakashima R; Yano T; Ogawa J; Tanaka N; Toda N; Yoshida M; Takano R; Inoue M; Honda T; Kume S; Matsumoto K
    Eur J Pharmacol; 2014 Aug; 737():194-201. PubMed ID: 24858371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and evaluation of a series of novel phenylpropanoic acid derivatives agonists for the FFA1.
    Yang J; Gu E; Yan T; Shen D; Feng B; Tang C
    Chem Biol Drug Des; 2019 May; 93(5):900-909. PubMed ID: 30657643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CPL207280, a Novel G Protein-Coupled Receptor 40/Free Fatty Acid Receptor 1-Specific Agonist, Shows a Favorable Safety Profile and Exerts Antidiabetic Effects in Type 2 Diabetic Animals.
    Bazydlo-Guzenda K; Buda P; Matloka M; Mach M; Stelmach F; Dzida R; Smuga D; Hucz-Kalitowska J; Teska-Kaminska M; Vialichka V; Dubiel K; Kaminska B; Wieczorek M; Pieczykolan J
    Mol Pharmacol; 2021 Oct; 100(4):335-347. PubMed ID: 34349026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and SAR of a novel series of heterocyclic phenylpropanoic acids as GPR120 agonists.
    Zhang X; Cai C; Winters M; Wells M; Wall M; Lanter J; Sui Z; Ma J; Novack A; Nashashibi I; Wang Y; Yan W; Suckow A; Hua H; Bell A; Haug P; Clapper W; Jenkinson C; Gunnet J; Leonard J; Murray WV
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3272-3278. PubMed ID: 28642104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GPR40 agonists for the treatment of type 2 diabetes mellitus: The biological characteristics and the chemical space.
    Chen C; Li H; Long YQ
    Bioorg Med Chem Lett; 2016 Dec; 26(23):5603-5612. PubMed ID: 27825762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and structure-activity relationship studies of GPR40 agonists containing amide linker.
    Chen T; Ning M; Ye Y; Wang K; Leng Y; Shen J
    Eur J Med Chem; 2018 May; 152():175-194. PubMed ID: 29705709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of novel potent GPR40 agonists containing imidazo[1,2-a]pyridine core as antidiabetic agents.
    Ye Z; Liu C; Zou F; Cai Y; Chen B; Zou Y; Mo J; Han T; Huang W; Qiu Q; Qian H
    Bioorg Med Chem; 2020 Jul; 28(13):115574. PubMed ID: 32546302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).
    Hamdouchi C; Kahl SD; Patel Lewis A; Cardona GR; Zink RW; Chen K; Eessalu TE; Ficorilli JV; Marcelo MC; Otto KA; Wilbur KL; Lineswala JP; Piper JL; Coffey DS; Sweetana SA; Haas JV; Brooks DA; Pratt EJ; Belin RM; Deeg MA; Ma X; Cannady EA; Johnson JT; Yumibe NP; Chen Q; Maiti P; Montrose-Rafizadeh C; Chen Y; Reifel Miller A
    J Med Chem; 2016 Dec; 59(24):10891-10916. PubMed ID: 27749056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with favorable physicochemical and in vitro ADME properties.
    Christiansen E; Urban C; Grundmann M; Due-Hansen ME; Hagesaether E; Schmidt J; Pardo L; Ullrich S; Kostenis E; Kassack M; Ulven T
    J Med Chem; 2011 Oct; 54(19):6691-703. PubMed ID: 21854074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulating GPR40: therapeutic promise and potential in diabetes.
    Poitout V; Lin DC
    Drug Discov Today; 2013 Dec; 18(23-24):1301-8. PubMed ID: 24051395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and biological evaluation of GPR40/FFAR1 agonists containing 3,5-dimethylisoxazole.
    Yang L; Zhang J; Si L; Han L; Zhang B; Ma H; Xing J; Zhao L; Zhou J; Zhang H
    Eur J Med Chem; 2016 Jun; 116():46-58. PubMed ID: 27054485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of a Potent Free Fatty Acid 1 Receptor Agonist with Low Lipophilicity, Low Polar Surface Area, and Robust in Vivo Efficacy.
    Hansen SV; Christiansen E; Urban C; Hudson BD; Stocker CJ; Due-Hansen ME; Wargent ET; Shimpukade B; Almeida R; Ejsing CS; Cawthorne MA; Kassack MU; Milligan G; Ulven T
    J Med Chem; 2016 Mar; 59(6):2841-6. PubMed ID: 26928019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring bulky natural and natural-like periphery in the design of p-(benzyloxy)phenylpropionic acid agonists of free fatty acid receptor 1 (GPR40).
    Kuranov SO; Luzina OA; Onopchenko O; Pishel I; Zozulya S; Gureev M; Salakhutdinov NF; Krasavin M
    Bioorg Chem; 2020 Jun; 99():103830. PubMed ID: 32289588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.